Search
Asfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalBy replacing deficient ALP, treatment with Asfotase Alfa aims to improve the elevated enzyme substrate levels and improve the body's ability to mineralize bone, thereby preventing serious skeletal and … by the U.S.
Sofosbuvir
go.drugbank.com/drugs/DB08934ApprovedInvestigationalSofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C … This is an important advantage relative to HCV drugs that target other viral enzymes such as the protease, for which rapid development of resistance has proven to be an important cause of therapeutic failure
Allogeneic processed thymus tissue
go.drugbank.com/drugs/DB16736Approved[L38929] Congenital athymia is a rare condition that leads to the absence of a thymus at birth and a high premature mortality rate, with patients typically dying by age two or three. … Allogeneic processed thymus tissue implantation works by migrating the recipient’s bone marrow-derived stem cells to the implanted cultured thymus tissue that develops immunocompetent naïve T cells.
Dihydroergotamine
go.drugbank.com/drugs/DB00320ApprovedInvestigational[L38469] Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. … Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeInclisiran
go.drugbank.com/drugs/DB14901ApprovedInvestigationalBy binding to PCSK9 messenger RNA, inclisiran prevents protein translation of PCSK9, leading to decreased concentrations of PCSK9 and plasma concentrations of LDL cholesterol. … [L28178] Inclisiran was later approved by the FDA on December 22, 2021, for the treatment of heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease in adults
Rituximab
go.drugbank.com/drugs/DB00073ApprovedInvestigationalIt was originally approved by the U.S. … On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808].
Insulin detemir
go.drugbank.com/drugs/DB01307ApprovedInvestigational[A2358, A2359, A2360, A44] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells … Insulin detemir is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.
Darbepoetin alfa
go.drugbank.com/drugs/DB00012ApprovedInvestigationalHuman erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
Crotalus atrox antivenin
go.drugbank.com/drugs/DB13892ApprovedIt is intravenously (IV) administered to prevent/limit systemic toxicity [FDA label]. … The majority of people bitten are males and about 50% occur in the age group of 18 to 28 [F113].
Enoxaparin
go.drugbank.com/drugs/DB01225ApprovedInvestigational[L31393] Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated [heparin], without increasing the risk of serious bleeding. … Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies.
Products: CLEXANE T, TROMBENOX T